Work

Phase Ib study of PF-04136309 (an oral CCR2 inhibitor) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic adenocarcinoma

Year: 2017

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1093/annonc/mdx369.132

Authors: M. Noel, M. Lowery, D. Ryan, B. Wolpin, A. Bullock, C. Britten, B. Jin, B.J. Ganguly, C.T. Taylor, D. Yin, D.A. Wunderlich, E.C. Gamelin, D.C. Linehan

Institutions: University of Rochester Medicine, Memorial Sloan Kettering Cancer Center, Massachusetts General Hospital, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Medical University of South Carolina, MUSC Hollings Cancer Center, Pfizer (United States)

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2762618241

FWCI: 0.541

Cites:

Cited by: 11

Related to: 10